Download Docs
Export
Print

CANTEX

98043024 | Trademark

Interested in this case?

To schedule a demo, contact us at sales@docketalarm.com. Track this case, and find millions of cases like it, let us show you how.
Filed June 14, 2023
Serial No. 98043024
Examining Attorney AMANDA A MILLER
Class Pharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; 005; 006; 018; 044; 046; 051; 052
CANTEX
Case Type Trademark
Status A non-final Office Action has been sent (issued) to the applicant after review of the Statement of Use. This is a letter from the examining attorney requiring additional information and/or making an initial refusal. The applicant must respond. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Last Updated: 6 days, 23 hours ago
Filing Date # Docket Text